| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1093/HUMUPD/DMI028 |
| P698 | PubMed publication ID | 16150813 |
| P2093 | author name string | Pier Giorgio Crosignani | |
| John A Collins | |||
| Jennifer M Blake | |||
| P433 | issue | 6 | |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 545-560 | |
| P577 | publication date | 2005-09-08 | |
| P1433 | published in | Human Reproduction Update | Q15724523 |
| P1476 | title | Breast cancer risk with postmenopausal hormonal treatment | |
| P478 | volume | 11 |
| Q35092002 | A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients |
| Q38542170 | Association of endometriosis and breast cancer: mini review of the literature |
| Q43267033 | Breast cancer from oral and transdermal estradiol: a cohort study of Finnish women |
| Q53573050 | Breast tumours following combined hormone replacement therapy express favourable prognostic factors. |
| Q33710365 | Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish women |
| Q36796694 | Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate |
| Q43254264 | Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland |
| Q37776847 | ERR receptors as potential targets in osteoporosis |
| Q36885708 | Effects of tibolone on the breast of postmenopausal women |
| Q30319186 | Established and Suspected Risk Factors in Breast Cancer Aetiology |
| Q30239742 | Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis |
| Q24658109 | Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society |
| Q88604005 | Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study |
| Q43276874 | Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? |
| Q46251423 | Expression of the androgen receptor and syndecan-1 in breast tissue during different hormonal treatments in cynomolgus monkeys |
| Q33751046 | Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy |
| Q39852950 | Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes |
| Q30491822 | Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk |
| Q43581949 | Hormone replacement therapy and some risk factors for breast cancer among Slovenian postmenopausal women |
| Q37909897 | Hormone replacement therapy and the risk of breast cancer |
| Q37016116 | Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen |
| Q28307740 | Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women |
| Q50646794 | Natural cycle as first approach in aged patients with elevated follicle-stimulating hormone undergoing intracytoplasmic sperm injection: a pilot study. |
| Q35674373 | One more look at guidelines for primary and secondary prevention of cardiovascular disease in women |
| Q33248076 | Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors |
| Q53667640 | Postmenopausal hormone therapy and ductal carcinoma in situ: a population-based case-control study. |
| Q30451123 | Postmenopausal hormone therapy: an Endocrine Society scientific statement. |
| Q90073087 | Progesterone and Breast Cancer |
| Q34317537 | Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects |
| Q27011732 | Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved? |
| Q27318225 | Repression of osteoblast maturation by ERRα accounts for bone loss induced by estrogen deficiency |
| Q54110608 | Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. |
| Q35335557 | Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk |
| Q36885714 | Standard and low-dose hormone therapy for postmenopausal women--focus on the breast |
| Q34762947 | The Mammary Glands of Macaques |
| Q37438166 | The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patients |
| Q34590315 | The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene |
| Q44141245 | Use of estradiol-progestin therapy associates with increased risk for uterine sarcomas |
| Q31032088 | Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment |
| Q37389691 | Vaginal Estrogen Therapy for Patients with Breast Cancer |
| Q37972785 | Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors |
Search more.